ExploreWatchlistsPricing
  1. JP-listed companies
  2. StemRIM Inc.
  3. Financials
  4. Cash from operations

StemRIM Inc. (4599)

Market cap
¥19.3B
P/E ratio
StemRim develops regenerative induction pharmaceuticals that activate patients' own stem cells to repair damaged tissues using peptide-based drugs like Ledasemdide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from operations (Million JPY)YoY (%)
Jul 31, 2025-1,415-24.81%
Jul 31, 2024-1,881-265.72%
Jul 31, 20231,135-180.83%
Jul 31, 2022-1,405+170.29%
Jul 31, 2021-520-190.31%
Jul 31, 2020575-173.98%
Jul 31, 2019-778+198.03%
Jul 31, 2018-261

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat